Steiner G (December 2007). “Atherosclerosis in type 2 diabetes: a role for fibrate therapy?”. Diab Vasc Dis Res4 (4): 368–74. doi:10.3132/dvdr.2007.067. PMID18158710.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009). “Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review”. Am J Med122 (10): 962.e1–962.e8. doi:10.1016/j.amjmed.2009.03.030. PMID19698935.
Jun M, Foote C, Lv J, et al. (2010). “Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis”. Lancet375 (9729): 1875–1884. doi:10.1016/S0140-6736(10)60656-3.
Steiner G (December 2007). “Atherosclerosis in type 2 diabetes: a role for fibrate therapy?”. Diab Vasc Dis Res4 (4): 368–74. doi:10.3132/dvdr.2007.067. PMID18158710.
Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ (2009). “Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review”. Am J Med122 (10): 962.e1–962.e8. doi:10.1016/j.amjmed.2009.03.030. PMID19698935.
Wysocki J1, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z (2004). “Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome”. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS42 (4): 212-217. PMID 15124979.